GSK's mRNA flu vaccine finally overcomes tricky B strains in phase 2 trial

After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all-important population of older adults.